

Supplementary Table 2. Patients' characteristics according to TILs, Immunoscoring[®], Immunoscoring-IC[®] and PDL1-TPS in pMMR subgroup

Characteristics	Population assessed for TILs N=167			Population assessed for Immunoscoring [®] N=69			Population assessed for Immunoscoring-IC [®] N=147			Population assessed for PDL1 N=148		
	TILs high N=59 n (%)	TILs low N=108 n (%)	<i>p</i>	Immunoscoring high N=40 n (%)	Immunoscoring low N=29 n (%)	<i>p</i>	Immunoscoring-IC high N=47 n (%)	Immunoscoring-IC low N=100 n (%)	<i>p</i>	PDL1 High N=17 n (%)	PDL1 Low N=131 n (%)	<i>p</i>
Age (years)												
Median	58	62	0.11 ¹	62	58	0.11 ¹	60	62	0.94 ¹	56	62	0.019¹
Range	(20-75)	(36-75)		(40-75)	(38-74)		(41-75)	(20-75)		(41-71)	(20-75)	
Sex												
Male	37 (63)	62 (57)	0.50 ²	25 (63)	18 (62)	0.97 ²	25 (53)	65 (65)	0.17 ²	8 (47)	83 (63)	0.20 ²
Female	22 (37)	46 (43)		15 (37)	11 (38)		22 (47)	35 (35)		9 (53)	48 (37)	
ECOG-PS												
0	49 (83)	93 (86)	0.60 ²	38 (95)	24 (83)	0.12 ³	42 (89)	80 (80)	0.16 ²	15 (88)	108 (82)	0.74 ³
1-2	10 (17)	15 (14)		2 (5)	5 (17)		5 (11)	20 (20)		2 (12)	23 (18)	
Site of Primary Tumor												
Right	26 (44)	41 (38)	0.44 ²	22 (55)	12 (41)	0.26 ²	20 (43)	41 (41)	0.86 ²	5 (29)	56 (43)	0.29 ²
Left and rectum	33 (56)	67 (62)		18 (45)	17 (59)		27 (57)	59 (59)		12 (71)	75 (57)	
RAS/BRAF mutational status												
RAS/BRAF wt	7 (12)	18 (17)	0.58 ²	5 (12)	5 (17)	0.84 ²	8 (17)	13 (13)	0.19 ²	1 (6)	20 (15)	0.32 ²
RAS mut	45 (76)	80 (75)		30 (75)	21 (72)		31 (67)	80 (80)		13 (76)	99 (76)	
BRAF mut	7 (12)	9 (8)		5 (12)	3 (10)		7 (15)	7 (7)		3 (18)	11 (9)	
NA	-	1		-	-		1	-		-	1	
Resected Primary Tumor												
Yes	20 (34)	55 (51)	0.035²	36 (90)	28 (97)	0.39 ³	17 (36)	53 (53)	0.057 ²	8 (47)	62 (47)	0.98 ²
No	39 (66)	53 (49)		4 (10)	1 (3)		30 (64)	47 (47)		9 (53)	69 (53)	
Prior adjuvant chemotherapy												
Yes	3 (5)	4 (4)	0.70 ³	2 (5)	2 (7)	1.0 ³	1 (2)	5 (5)	0.66 ³	2 (12)	4 (3)	0.14 ³

No	56 (95)	104 (96)		38 (95)	27 (93)		46 (98)	95 (95)		15 (88)	127 (97)	
Number of metastatic sites												
1	31 (53)	40 (37)	0.053 ²	17 (42)	12 (41)	0.93 ²	22 (47)	33 (33)	0.11 ²	8 (47)	47 (36)	0.37 ²
>1	28 (47)	68 (63)		23 (58)	17 (59)		25 (53)	67 (67)		9 (53)	84 (64)	
Liver Only Disease												
Yes	18 (30)	28 (26)	0.53 ²	9 (22)	10 (34)	0.27 ²	15 (32)	24 (24)	0.31 ²	6 (35)	33 (25)	0.38 ²
No	41 (70)	80 (74)		31 (78)	19 (66)		32 (68)	76 (76)		11 (65)	98 (75)	
Liver metastases												
Yes	38 (64)	88 (81)	0.015 ²	26 (65)	24 (83)	0.092 ²	32 (68)	82 (82)	0.060 ²	15 (88)	99 (76)	0.36 ³
No	21 (36)	20 (19)		14 (35)	5 (17)		15 (32)	18 (18)		2 (12)	32 (24)	
Time to Metastases												
Synchronous	51 (86)	16 (15)	0.83 ²	26 (65)	24 (83)	0.10 ²	40 (85)	84 (84)	0.86 ²	14 (82)	111 (85)	0.73 ³
Metachronous	8 (14)	92 (85)		14 (35)	5 (17)		7 (15)	16 (16)		3 (18)	20 (15)	
Treatment arm												
FOLFOXIRI/bev	16 (27)	44 (41)	0.080 ²	10 (25)	10 (34)	0.39 ²	16 (34)	36 (36)	0.82 ²	5 (29)	47 (36)	0.60 ²
FOLFOXIRI/bev/atezo	43 (73)	64 (59)		30 (75)	19 (66)		31 (66)	64 (64)		12 (71)	84 (34)	
Tumour mutational burden												
High (≥10 mut/Mb)	2 (5)	4 (5)	1.0 ³	4 (12)	-	0.13 ³	5 (17)	2 (2)	0.016 ³	-	7 (7)	1.0 ³
Low (<10 mut/Mb)	36 (95)	77 (95)		30 (88)	25 (100)		25 (83)	78 (98)		11 (100)	92 (93)	
NA	21	27		6	4		17	20		6	32	

Legend: pMMR: proficient mismatch repair; N: number; TPS: Tumor Proportion Score; PDL1: Programmed death-ligand 1; ECOG-PS: Eastern Cooperative Oncology Group Performance Status; NA: not available; mut: mutated; wt: wild-type.

¹Kruskal-Wallis p-value; ²Chi-Square p-value; ³Fisher p-value;